indium In 111-DOTA-daratumumab

A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the radioisotope indium In 111, with potential use as an imaging agent. Upon administration, the monoclonal antibody moiety of indium In 111-DOTA-daratumumab specifically targets and binds to cell surface antigen CD38. Upon binding and gamma scintigraphy, CD38-expressing tumor cells can be visualized, and the binding and biodistribution of daratumumab can be assessed. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.